EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases

Limin Dou iD, Fuying Chen, Wei He, Jianbo Wang, Chenfei Wang, Xiaotian Chen, Xiaomin Peng, Liuhui Wang, Ying Ye, Ming Li

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Limin Dou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Antibodies, Monoclonal, Humanized, Pruritus, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Nature Science Foundation of China (82203949), Shanghai Sailing Program (22YF1436600) and Medical Engineering Cross Research Foundation of Shanghai Ji…, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dystrophic epidermolysis bullosa (DEB) is a genetic skin disease with limited therapeutic options for managing pruritus. This study retrospectively evaluated the efficacy and safety of Dupilumab monotherapy in patients with DEB suffering from severe pruritus. DEB patients treated with Dupilumab between June 2021 and June 2023 were reviewed. DEB severity and pruritus intensity were assessed using the Birmingham Epidermolysis Bullosa Severity (BEBS, range 0–100) scores and the Numerical Rating Scale (NRS, range 0–10), respectively. A linear mixed model was used to evaluate the changes in NRS scores of Dupilumab monotherapy over time. The Wilcoxon signed‐rank test was used to compare the differences in BEBS scores between pretreatment and posttreatment. Statistical significance was defined as p < 0.05. Eight patients were included (four males and four females; aged 5–38 years). Subtypes included severe ( n = 4), intermediate ( n = 2), pruriginosa RDEB ( n = 1), or pruriginosa DDEB ( n = 1). The baseline NRS scores averaged 8.75 ± 1.04, with significant reductions of 58.51%, 60.00%, and 49.94% at 4, 8, and 12 weeks, respectively ( p < 0.001). The mean BEBS score at baseline was 35.36 ± 21.47, decreased by 22.29% at 12 weeks ( p = 0.049), while the mean area of damaged skin score was 19.63 ± 1.71 at baseline, decreased by 31.23% after 12 weeks ( p = 0.048). The mean duration of Dupilumab treatment was 44.50 (12–130) weeks. One DDEB‐Pr patient discontinued Dupilumab for planned conception, with no adverse effects reported for the pregnant woman or newborn. Dupilumab appears to be a safe and effective treatment for pruritus in patients with DEB. Preliminary findings also support its potential use in women of reproductive age. Further larger prospective studies are needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epidermolysis Bullosa DystrophicaAntibodies, Monoclonal, HumanizedPruritusDermatologic AgentsHumansFemaleRetrospective StudiesMaleAdultChildAdolescentChild, PreschoolTreatment OutcomeYoung AdultSeverity of Illness Index

Stichwörter der Autor:innen

Dupilumabdystrophic epidermolysis bullosaprurituswomen of reproductive agewound

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
  • Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
  • Department of Clinical Epidemiology and Clinical Trial Unit, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
  • Center for Translational Medicine, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.

ORCID-Profile: Limin Dou

Förderung

  • National Nature Science Foundation of China (82203949), Shanghai Sailing Program (22YF1436600) and Medical Engineering Cross Research Foundation of Shanghai Ji…
  • National Natural Science Foundation of China

Zitieren

APA

Dou, L., Chen, F., He, W., Wang, J., Wang, C., Chen, X., Peng, X., Wang, L., Ye, Y., & Li, M. (2025). Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17753

Vancouver

Dou L, Chen F, He W, Wang J, Wang C, Chen X, et al. Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17753

BibTeX
@article{Dou2025,
  author = {Dou, Limin and Chen, Fuying and He, Wei and Wang, Jianbo and Wang, Chenfei and Chen, Xiaotian and Peng, Xiaomin and Wang, Liuhui and Ye, Ying and Li, Ming},
  title = {Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17753}
}
Kostenlos starten →